Oramed Pharmaceuticals is UNDERVALUED at 6.46 per share with modest projections ahead. We provide trade recommendations to complement the recent
expert consensus on Oramed Pharmaceuticals. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of Oramed Pharmaceuticals? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
What is happening with Oramed Pharmaceuticals this year
Annual and quarterly reports issued by Oramed Pharmaceuticals are formal
financial statements that are published yearly and quarterly and sent to Oramed stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Oramed Pharmaceuticals often view their annual report as an effective marketing tool to disseminate their perspective on company
future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Oramed Pharmaceuticals Gross Profit
Oramed Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Oramed Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Oramed Pharmaceuticals Gross Profit growth over the last 10 years. Please check Oramed Pharmaceuticals'
gross profit and other
fundamental indicators for more details.
Is Oramed a risky opportunity?
Let's check the volatility. Oramed is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Oramed (NASDAQ:ORMP) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. obtaining a share of an Oramed Pharmaceuticals stock makes you a part-owner of that company.
Oramed Pharmaceuticals Current Consensus
Here is the recent trade recommendation based on an ongoing consensus estimate among financial analysis covering Oramed Pharmaceuticals. The Oramed consensus assessment is calculated by taking the average estimates from all of the analysts covering Oramed Pharmaceuticals
| Strong Buy | 3 | 100.0 |
| Buy | 0 | 0.0 |
| Hold | 0 | 0.0 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Our perspective of the recent Oramed Pharmaceuticals roll up
Kurtosis is down to 17.04. It may hint at a possible volatility decline. As of the 28th of November, Oramed Pharmaceuticals holds the Coefficient Of Variation of 1176.48,
risk adjusted performance of 0.115, and Semi Deviation of 3.8. Compared to
fundamental indicators, the
technical analysis model allows you to check existing technical drivers of Oramed Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to analyze and collect data for nineteen
technical drivers for Oramed Pharmaceuticals, which can be compared to its competitors. Please check
Oramed Pharmaceuticals standard deviation, as well as the
relationship between the maximum drawdown and
expected short fall to decide if Oramed Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 4.45 per share. Given that Oramed Pharmaceuticals has
jensen alpha of 0.4741, we recommend you to check out Oramed Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.
Our Takeaway on Oramed Pharmaceuticals Investment
Although other entities under the biotechnology industry are still a bit expensive, Oramed Pharmaceuticals may offer a potential longer-term growth to insiders. While some insiders may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Oramed Pharmaceuticals.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Oramed Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
